LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
28.57
+0.14 (0.49%)
Nov 5, 2024, 3:49 PM EST - Market open

LENZ Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21
Revenue
--15-
Gross Profit
--15-
Selling, General & Admin
21.2712.934.362.47
Research & Development
54.0259.521.134.22
Operating Expenses
75.2972.4325.486.69
Operating Income
-75.29-72.43-10.48-6.69
Interest & Investment Income
5.192.190-
Other Non Operating Income (Expenses)
0.450.090.02-0.87
Pretax Income
-69.65-70.15-10.46-7.56
Income Tax Expense
-0.18-0.180.35-
Net Income
-69.47-69.97-10.81-7.56
Net Income to Common
-69.47-69.97-10.81-7.56
Shares Outstanding (Basic)
161099
Shares Outstanding (Diluted)
161099
Shares Change (YoY)
72.32%2.47%1.05%-
EPS (Basic)
-4.26-7.22-1.14-0.81
EPS (Diluted)
-4.26-7.22-1.14-0.81
Free Cash Flow
-73.92-60.41-4.13-5.4
Free Cash Flow Per Share
-4.54-6.23-0.44-0.58
Gross Margin
--100.00%-
Operating Margin
---69.89%-
Profit Margin
---72.07%-
Free Cash Flow Margin
---27.52%-
EBITDA
-75.26-72.41-10.48-6.69
EBITDA Margin
---69.83%-
D&A For EBITDA
0.030.020.010
EBIT
-75.29-72.43-10.48-6.69
EBIT Margin
---69.89%-
Revenue as Reported
--15-
Source: S&P Capital IQ. Standard template. Financial Sources.